obesity

News

Pfizer drops twice-daily obesity therapy due to side effects

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

News

AHA: Wegovy improves survival in outcomes trial

Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by 19% in the SELECT trial, mirroring the benefits of the drug in cardiovascular outcomes in people who are

R&D

While diabetes & obesity fund Novo Nordisk, its Foundation f...

The Novo Nordisk Foundation is not a charitable organisation owned by the pharma company Novo Nordisk. In fact, it’s the other way around, more or less.

News

AstraZeneca builds in obesity with $2bn+ Eccogene deal

AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist

News

Lilly gets FDA okay for tirzepatide as obesity therapy

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a

Pfizer drops twice-daily obesity therapy due to side effects

Roche makes obesity play with $2.7bn deal to buy Carmot

AHA: Wegovy improves survival in outcomes trial

While diabetes & obesity fund Novo Nordisk, its Foundation f...

AstraZeneca builds in obesity with $2bn+ Eccogene deal

Lilly gets FDA okay for tirzepatide as obesity therapy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

obesity

Editor's Picks